Molecular Diagnostics

分子诊断

• 批准号: 9071315
• 负责人: JAMES Lewis ZEHNDER
• 金额: $ 23.95万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9071315
• 关键词: Animal Model; B cell repertoire; Biological; Biological Assay; Bone Marrow Transplantation; Chemistry; Clinical; Custom; Data; Detection of Minimal Residual Disease; Diagnostic; Disease; Disease Progression; Early Diagnosis; Ensure; Gene Rearrangement; Goals; Gold; Immune; Instruction; Intervention; Investigational Therapies; Massive Parallel Sequencing; Methods; Molecular; Molecular Analysis; Molecular Profiling; Monitor; Patients; Performance; Play; Procedures; Program Research Project Grants; Recurrence; Relapse; Research Personnel; Residual Neoplasm; Reverse Transcriptase Polymerase Chain Reaction; Role; Services; Specimen; Technology; Testing; Time; Tissue Sample; Transplantation; Treatment outcome; Work; base; clinical care; cost; gene translocation; hematopoietic cell transplantation; improved; innovation; leukemia/lymphoma; meetings; molecular diagnostics; molecular marker; molecular pathology; next generation; next generation sequencing; novel; preclinical study; programs; reconstitution; response; tool; treatment group

The role of the Molecular Pathology Core is to support investigators in the Program Project Grant by providing dedicated molecular biological analyses for effective assessment of disease states, the molecular basis of response to therapy both in patients and in animal models, and the analysis of immune reconstitution following transplant interventions. The services provided by this Core are those that extend beyond routine preclinical studies and standard clinical care. This Core provides molecular testing for projects that monitor treatment outcomes, detect eariy disease recurrence and minimal disease states. Rapid and quantitative assessment of experimental therapies is necessary for accelerated and accurate analyses of potential efficacy. Quantitative assessment of minimal residual disease will be performed using TaqMan chemistry for a robust assessment of disease response and potential recurrence on clinical specimens. The core will utilize novel, massively parallel next generation sequencing technology in addition to the standard real-time PCR methods to improve detection of minimal residual disease and provide an assessment of immune reconstitution. The centralized performance of the molecular procedures by this Core will avoid duplication of efforts in the program and ensure timely, efficient and consistently high quality results.

分子病理学核心的作用是通过提供专门的分子生物学分析来有效评估疾病状态，患者和动物模型对治疗反应的分子基础，以及移植干预后免疫重建的分析，来支持计划项目资助的研究人员。这个核心提供的服务是那些扩展的服务